Biophysium

Cardiovascular health

Cardiovascular health

Cardiovascular diseases are the leading cause of disability and premature death in the world. Consequently, these pathologies constitute a major public health problem. According to the WHO, in 2030 nearly 23.6 million people will die of cardiovascular disease per year and according to projections, these diseases will remain the first cause of mortality in front of cancers. Cardiovascular system disorders include a number of conditions that can impair myocardial morphology and function such as myocardial ischemia, valvular pathologies, heart failure, rhythm disorders, endothelial dysfunction, coronary artery disease, peripheral arterial disease and high blood pressure. The proper functioning of the cardiovascular system remains a major concern and development of innovative treatments to preserve it a priority.

Thus, reducing the frequency of clinical events and premature mortality in people with advanced cardiovascular pathology and in people whose risk is increased by the presence of one or more risk factors is a major objective. Biophysium’s competences allow you to evaluate cardiovascular dysfunctions which can be linked to a metabolic pathology (diabetes, obesity, metabolic syndrome, hyperglycemia, lipid oxidation, etc.), a clinical event such as a myocardial infarction or as the consequence of a toxic treatment.

cardiographie
cardiographie

We will also provide the tools to evaluate the potential effects of preventive or rehabilitation strategies such as medications, physical activity or nutritional interventions. Our expertise will allow us to assess specifically the generation of oxidative stress (cytosolic or mitochondrial), the nitric oxide pathway, inflammation as well as other biomarkers. Moreover, metabolomic and proteomic analyses will allow you to bring mechanistic elements to your proof of concept.

In order to meet your requirements, we are able to use different rodent models obtained by pharmacological interventions, diet modifications but also genetically modified models. The recording of basic physiological parameters (weight, food intake, behavior) is common to all our animal models.

Cell culture
cellule

Endothelial cells

Smooth muscle cells

Angiogenesis

Adipocyte

Macrophage

Pre-clinical models
rongeur

Arterial hypertension

In vivo or ex vivo myocardial ischemia

Heart failure

Cardiac fatigue

Dyslipidemia and Atherosclerosis

 ApoE-/- or KO mice for LDL receptor

Hypercholesterolemia

 Obesity

(High Fat diet, ob/ob rat and db/db mouse)

Type 1 or 2 Diabetes

(Zucker or Goto-Kakizaki rat, DT-1 – streptozotocine)

Acute hyperglycemia

Hyperlipidemia

Voluntary or imposed exercise

(wheel and treadmill)

Performance test

(MAS, VO2 max)

Customized diet adapted to your project

Any other genetic or induced rat or mouse model

Isolated cardiomyocyte

Oxydative stress production

Mitochondrial function

Calcium retention capacity, fusion, fission, swelling, oxidative stress

Samples : urine, feces, blood or tissue/organ

Product administration

Injection, gavage, drinking water, food

Pulmonary hypertension

Clinical models
clinique

Overweight/Obese

Diabetic

Cardiovascular risk factors

Voluntary or imposed physical exercise

Microcirculatory function

Fitness and performance evaluation

Functional exploration

Human: high resolution echocardiography at rest or under stress conditions
(dobutamine, exercise, etc..)

Myocardial remodeling,ventricular or atrial myocardial deformations, twist and untwist mechanism, myocardial work

Heart rate variability

Physical test

gas exchange, VO2 max, MAS

Telemetry monitoring

 

 

Cardiac and vascular imaging by ultrasound

Systolic and diastolic function, regional myocardial deformation, cardiac and vascular morphology, cardiac and vascular remodeling

Microcirculatory function

Body composition

Urinary and blood biomarkers

Lipid and oxidized lipid profile (cholesterol and LDL), carbohydrate profile, inflammatory cytokines, metabolomic, oxidative stress, MicroRNA

Electrocardiogram

Isolated perfused heart model of Langendorff

Endothelial function

Arterial pressure by non-invasive plethysmography Tail cuff method

Millar probe : left ventricular presure and volume loops

Calcium transient and contractility

Perfusion Flow

Laser speckle contrast imaging

Technical plateform

Surgical procedure

Millar, transonic, myocardial ischemia, acute hyperglycemia

Glucose dans lipid homeostasis 

Infarct size area by planimetry

Measurement of atheromatous plaque size by ultrasound, histology and colorimetry

Evaluation of atheromatous plaque characteristics (fibrosis, macrophage infiltration) by histology

Isolated vessel model and vasoreactivity test (aorta, coronary, pulmonary artery, femoral, intra-pulmonary)

Blood lipid profile 

TG, HDL, LDL, cholesterol

oxydation

 Cholesterol and LDL

Isolated cardiomyocyte and mitochondria

Oxidative stress and nitric oxide production, calcium retention cycle, immunofluorescence

Urinary, faecal, tissue and blood specific biomarkers

Biochemistery & translational approach
biochimie

Biochemical tests

Western blot, ELISA kit, protein activity, S-nitrosoproteomic

Histology for characterization

Hematoxylin-eosin, Sirius Red, Oil-Red-O, Masson Trichome, PAS staining, right ventricle morphology, immunohistology at request

Confocal and fluorescent microscopy

Mitochondrial function

Calcium retention, fusion, fission, swelling

S-Nitrosylation, cytosolic and mitochondrial regulation of oxidative stress production

Metabolomic and proteomic through mass spectrometry

Evaluation of cardiac and vascular oxidative stress and inflammation

 Complete blood analysis

Tissue lipid oxidation

top

Top